AR118601A2 - Formulaciones sólidas estables de un receptor gc-c, agonista polipeptídico adecuado para administración oral - Google Patents

Formulaciones sólidas estables de un receptor gc-c, agonista polipeptídico adecuado para administración oral

Info

Publication number
AR118601A2
AR118601A2 ARP200100962A ARP200100962A AR118601A2 AR 118601 A2 AR118601 A2 AR 118601A2 AR P200100962 A ARP200100962 A AR P200100962A AR P200100962 A ARP200100962 A AR P200100962A AR 118601 A2 AR118601 A2 AR 118601A2
Authority
AR
Argentina
Prior art keywords
cys
oral administration
formulations
linaclotide
stable solid
Prior art date
Application number
ARP200100962A
Other languages
English (en)
Original Assignee
Ironwood Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ironwood Pharmaceuticals Inc filed Critical Ironwood Pharmaceuticals Inc
Publication of AR118601A2 publication Critical patent/AR118601A2/es

Links

Classifications

    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02W—CLIMATE CHANGE MITIGATION TECHNOLOGIES RELATED TO WASTEWATER TREATMENT OR WASTE MANAGEMENT
    • Y02W90/00—Enabling technologies or technologies with a potential or indirect contribution to greenhouse gas [GHG] emissions mitigation
    • Y02W90/10—Bio-packaging, e.g. packing containers made from renewable resources or bio-plastics

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describen en la presente formulaciones sólidas estables de linaclotida adecuadas para la administración oral así como métodos para preparar dichas formulaciones. Las formulaciones descritas en la presente contienen un polipéptido que consiste de la secuencia de aminoácidos Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (“linaclotida”) o una de sus sales farmacéuticamente aceptables. Las formulaciones de linaclotida descritas en la presente son estables y tienen suficiente vida de depósito para fabricar, almacenar y distribuir el fármaco.
ARP200100962A 2008-08-15 2020-04-06 Formulaciones sólidas estables de un receptor gc-c, agonista polipeptídico adecuado para administración oral AR118601A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8942208P 2008-08-15 2008-08-15

Publications (1)

Publication Number Publication Date
AR118601A2 true AR118601A2 (es) 2021-10-20

Family

ID=56267523

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200100962A AR118601A2 (es) 2008-08-15 2020-04-06 Formulaciones sólidas estables de un receptor gc-c, agonista polipeptídico adecuado para administración oral

Country Status (2)

Country Link
AR (1) AR118601A2 (es)
UA (1) UA104870C2 (es)

Also Published As

Publication number Publication date
UA104870C2 (uk) 2014-03-25

Similar Documents

Publication Publication Date Title
CO6351746A2 (es) Formulación sólida estable de un polipéptido agonista de receptor gc-c adecuado para administración oral
CY1119243T1 (el) Φαρμακοτεχνικες μορφες ανταγωνιστη του vegf
CA2846209C (en) Systemic sustained release formulation comprising elastin­like peptide repeating sequence and protein active agent
CY1122853T1 (el) Σταθερα σκευασματα λινακλοτιδης
CY1123334T1 (el) Σκευασματα φιναστεριδης για αποδεσμευση φαρμακου στα μαλλια και στο τριχωτο της κεφαλης
TW200637615A (en) Therapeutic peptide formulations with improved stability
MX2016006053A (es) Compuestos selectivos de peptido yy (pyy) y usos de los mismos.
MX2007005521A (es) Formulaciones estables de peptidos insulinotropicos.
PH12014501642B1 (en) Peptide vaccines for cancers expressing tumor-associated antigens
WO2010027405A3 (en) Formulations of gc-c receptor agonist polypeptides
WO2009158704A3 (en) Therapeutic agents comprising elastin-like peptides
WO2009086400A3 (en) Recombinant vwf formulations
NZ621868A (en) Growth hormone polypeptides and methods of making and using same
RS53559B1 (en) INSULIN FORMULATIONS WITH LONG TERM ACTION
EP4403197A3 (en) Injectable formulations for organ augmentation
WO2009025196A1 (ja) Foxm1ペプチドおよびこれを含む薬剤
MY160652A (en) Pharmaceutical composition for oral administration
PE20142332A1 (es) Metodo y formulacion para reducir la agregacion de una macromolecula bajo condiciones fisiologicas
AR083528A1 (es) Analogos de peptido insulinotropico dependiente de glucosa
WO2010027404A3 (en) Stable formulation comprising therapeutic polypeptides for oral administration
AR088727A1 (es) Peptidos ciclicos con actividad antineoplasica y antiangiogenica
ZA200807027B (en) Peptides and peptide derivatives, the production thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition
AR118601A2 (es) Formulaciones sólidas estables de un receptor gc-c, agonista polipeptídico adecuado para administración oral
UY32054A (es) Formulación sólida estable de un polipéptido agonista de receptor gc-c adecuado para administración oral.
ECSP11010897A (es) Formulación sólida estable de un polipéptido agonista de receptor